MMJ PhytoTech Limited (ASX:MMJ) is pleased to advise that Canadian-based Harvest One Capital Corp. (CVE:WON.H) has closed the previously reported (January 27, 2017) private placement, raising C$25,000,500 before costs. Pursuant to the Placement, Harvest One issued 33,334,000 Subscription Receipts at a price of C$0.75.
Anatara Lifesciences Ltd (ASX:ANR) is pleased to provide the Company's Half Yearly Report for the period ended 31 December, 2016.
(NetworkNewsWire) Catalyst Pharmaceuticals, Inc. (NASDAQ:CPRX) on January 10, 2017, filed with the SEC a prospectus (http://nnw.fm/9sGg6) for the sale in the aggregate of $33,842,512 of its common stock. The use of proceeds will be to fund both clinical and non-clinical studies of its product candidates and for general working capital.
(NetworkNewsWire) The '2017 Disruptive Growth & Healthcare Conference', which ran February 15-16 at the Convene at 730 Third Avenue Conference Center in midtown Manhattan, New York, featured some stellar participants, either as presenters or as sponsors. Along with over 60 other firms in a variety of fields related to biotech, IntelliPharmaCeutics International, Inc. (NASDAQ:IPCI) (TSE:I) was on the bill.
Immuron Limited (ASX:IMC) (OTCMKTS:IMROY) wishes to advise investors that European and US-based Life Sciences Research and Analyst firm Van Leeuwenhoeck Institute, has published an updated in-depth Research Report on the Company and its R&D programs.
Imugene Limited (ASX:IMU) preclinical research related to HER-Vaxx (clinical name IMU-131) has been accepted and published in the prestigious journal BMC Cancer. IMU-131 is a next generation HER-2 cancer therapy using B cell peptides, which harness the body's ability to develop antibodies against the disease.
MMJ PhytoTech Ltd (ASX:MMJ) is pleased to advise that it has entered into a binding Letter of Intent with HL Pharma Pty Ltd. for the importation and distribution of the Company's medicinal cannabis products in Australia.
